{"id": "95e7f207-d45e-45c3-87c2-e452fa044e86", "page": 1, "type": "table", "data": [["HIGHLIGHTS OF PRESCRIBING INFORMATION", "\u2022 If Guillain-Barr\u00e9 syndrome has occurred within 6 weeks of\nreceipt of a prior"], ["", "in\ufb02uenza\nvaccine,\nthe\ndecision\nto\ngive\nFlublok\nshould\nbe\nbased\non\ncareful"], ["These highlights do not include all the information needed to use Flublok\u00ae safely", ""], ["and effectively. See full prescribing information for Flublok.", "consideration of potential bene\ufb01ts and risks.\n(5.2)"], ["Flublok (In\ufb02uenza Vaccine)", ""], ["Injection for\nIntramuscular Use 2024-2025 Formula", "\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\nADVERSE REACTIONS\n\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014"], ["Initial U.S. Approval: 2013", "\u2022 In adults 18 through 49 years of age,\nthe most common (\u226510%)\ninjection-site"], ["", "adverse reaction was pain (37%);\nthe most common (\u226510%) solicited systemic"], ["\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\nINDICATIONS AND USAGE\n\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014", "adverse reactions were headache (15%),\nfatigue (15%) and muscle pain (11%)."], ["Flublok is a vaccine indicated for active immunization for\nthe prevention of disease", "(6.1)"], ["caused by\nin\ufb02uenza A virus\nsubtypes and in\ufb02uenza type B virus\ncontained in the", ""], ["", "\u2022 In adults 50 through 64 years of age,\nthe most common (\u226510%)\ninjection site"], ["vaccine. Flublok is approved for use in persons 18 years of age and older.\n(1)", ""], ["", "adverse reaction was pain (32%);\nthe most common (\u226510%) solicited systemic"], ["", "adverse reactions were headache (17%),\nfatigue (13%), and muscle pain (11%)."], ["\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\nDOSAGE AND ADMINISTRATION\n\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014", ""], ["", "(6.1)"], ["For\nintramuscular use (0.5 mL).\n(2)", ""], ["", "\u2022 In adults 65 years of age and older,\nthe most\ncommon (\u226510%)\ninjection site"], ["\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\nDOSAGE FORMS AND STRENGTHS\n\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014", "adverse reaction was pain (19%);\nthe most common (\u226510%) solicited systemic"], ["Flublok is an injection, a single dose is 0.5mL.\n(3)", "adverse reactions were fatigue (13%) and headache (10%).\n(6.1)"], ["\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\nCONTRAINDICATIONS\n\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014", ""], ["", "To report SUSPECTED ADVERSE REACTIONS, contact Sano\ufb01 Pasteur\nInc., at"], ["\u2022 Do not administer Flublok to anyone with a history of severe allergic reactions", ""], ["", "(1-800-822-2463\n(1-800-Vaccine)\nor\nVAERS\nat\n1-800-822-7967\nor"], ["(e.g., anaphylaxis)\nto any component of\nthe vaccine.\n(4, 6.2, 11)", ""], ["", "www.vaers.hhs.gov."], ["\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\nWARNINGS AND PRECAUTIONS\n\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014", ""], ["", "See 17 for PATIENT COUNSELING INFORMATION"], ["\u2022 Appropriate medical\ntreatment must be immediately available to manage potential", ""], ["anaphylactic reactions following administration of Flublok.\n(5.1)", "Revised: 07/2024"]]}
{"id": "526f05ad-0563-445f-b494-a1b097f987a8", "page": 1, "type": "table", "data": [["", "", "See 17 for PATIENT COUNSELING INFORMATION", ""], ["\u2022 Appropriate medical\ntreatment must be immediately available to manage potential", "", "", ""], ["anaphylactic reactions following administration of Flublok.\n(5.1)", "", "", "Revised: 07/2024"], ["FULL PRESCRIBING INFORMATION: CONTENTS*", "8", "USE IN SPECIFIC POPULATIONS", ""], ["1\nINDICATIONS AND USAGE", "", "8.1\nPregnancy", ""], ["", "", "8.2\nLactation", ""], ["2\nDOSAGE AND ADMINISTRATION", "", "", ""], ["", "", "8.4\nPediatric Use", ""], ["2.1\nDosage", "", "", ""], ["", "", "8.5\nGeriatric Use", ""], ["2.2\nAdministration", "", "", ""], ["", "11", "DESCRIPTION", ""], ["3\nDOSAGE FORMS AND STRENGTHS", "", "", ""], ["", "12", "CLINICAL PHARMACOLOGY", ""], ["4\nCONTRAINDICATIONS", "", "12.1\nMechanism of Action", ""], ["5\nWARNINGS AND PRECAUTIONS", "13", "NONCLINICAL TOXICOLOGY", ""], ["5.1\nManaging Allergic Reactions", "", "13.1\nCarcinogenesis, Mutagenesis,\nImpairment of Fertility", ""], ["", "14", "CLINICAL STUDIES", ""], ["5.2\nGuillain-Barr\u00e9 Syndrome", "", "", ""], ["", "", "14.1\nEfficacy Against Laboratory-Con\ufb01rmed In\ufb02uenza", ""], ["5.3\nAltered Immunocompetence", "", "", ""], ["", "15", "REFERENCES", ""], ["5.4\nLimitations of Vaccine Effectiveness", "16", "HOW SUPPLIED/STORAGE AND HANDLING", ""], ["5.5\nSyncope", "", "16.1\nHow Supplied", ""], ["", "", "16.2\nStorage and Handling", ""], ["6\nADVERSE REACTIONS", "", "", ""], ["", "17", "PATIENT COUNSELING INFORMATION", ""], ["6.1\nClinical Trials Experience", "", "", ""], ["", "", "", "*Sections or subsections omitted from the full prescribing information are not"], ["6.2\nPostmarketing Experience", "", "listed", ""]]}
{"id": "86dd31b9-2f15-4e9c-844a-9dff5ba9f80c", "page": 1, "type": "table", "data": [["", "", "", "", "", "*Sections or subsections omitted from the full prescribing information are not"], ["6.2\nPostmarketing Experience", "", "", "", "", "listed"], ["FULL PRESCRIBING INFORMATION", "", "", "", "", "5.3\nAltered Immunocompetence"], ["1\nINDICATIONS AND USAGE", "", "", "", "", "If Flublok is administered to immunocompromised individuals,\nincluding persons receiving"], ["Flublok is a vaccine indicated for active immunization for the prevention of disease caused", "", "", "", "", "immunosuppressive therapy,\nthe immune response may be diminished."], ["", "", "", "", "", "5.4\nLimitations of Vaccine Effectiveness"], ["by in\ufb02uenza A virus subtypes and in\ufb02uenza type B virus contained in the vaccine. Flublok", "", "", "", "", ""], ["is approved for use in persons 18 years of age and older.", "", "", "", "", "Vaccination with Flublok may not protect all vaccine recipients."], ["", "", "", "", "", "5.5\nSyncope"], ["2\nDOSAGE AND ADMINISTRATION", "", "", "", "", ""], ["", "", "", "", "", "Syncope\n(fainting)\nhas\nbeen\nreported\nfollowing\nvaccination with Flublok. Procedures"], ["For\nintramuscular use.", "", "", "", "", ""], ["", "", "", "", "", "should be in place to avoid injury from fainting."], ["2.1\nDosage", "", "", "", "", ""], ["", "", "", "", "", "6\nADVERSE REACTIONS"], ["Administer Flublok as a single 0.5 mL dose.", "", "", "", "", ""], ["", "", "", "", "", "In adults 18 through 49 years of age,\nthe most common (\u226510%)\ninjection-site adverse"], ["2.2\nAdministration", "", "", "", "", ""], ["", "", "", "", "", "reaction was pain (37%);\nthe most common (\u226510%) solicited systemic adverse reactions"], ["Parenteral drug products should be inspected visually for particulate matter and discol-", "", "", "", "", ""], ["", "", "", "", "", "were headache (15%),\nfatigue (15%) and muscle pain (11%).\n(6.1)"], ["oration prior", "to administration whenever solution and container permit.", "", "If either of", "these", ""], ["", "", "", "", "", "In adults 50 through 64 years of age,\nthe most common (\u226510%)\ninjection site adverse"], ["conditions exists,\nthe vaccine should not be administered.", "", "", "", "", ""], ["", "", "", "", "", "reaction was pain (32%);\nthe most common (\u226510%) solicited systemic adverse reactions"], ["Gently invert\nthe pre\ufb01lled syringe prior", "to affixing a sterile needle.", "", "", "", ""], ["", "", "", "", "", "were headache (17%),\nfatigue (13%), and muscle pain (11%).\n(6.1)"], ["Administer\nthe dose intramuscularly.", "", "", "", "", "In adults 65 years of age and older,\nthe most common (\u226510%)\ninjection site adverse"], ["3\nDOSAGE FORMS AND STRENGTHS", "", "", "", "", ""], ["", "", "", "", "", "reaction was pain (19%);\nthe most common (\u226510%) solicited systemic adverse reactions"], ["Flublok is an injection. A single dose is 0.5 mL.", "", "", "", "", "were fatigue (13%) and headache (10%).\n(6.1)"], ["4\nCONTRAINDICATIONS", "", "", "", "", "6.1\nClinical Trials Experience"], ["Do not administer Flublok\nto anyone with a history of", "severe allergic", "", "reactions", "(e.g.,", "Because clinical studies are conducted under widely varying conditions, adverse reaction"], ["anaphylaxis)\nto any component of\nthe vaccine.", "[see Postmarketing Experience [6.2] and", "", "", "", "rates observed in the clinical studies of a vaccine cannot be directly compared to rates"], ["Description (11)].", "", "", "", "", "in the clinical studies of another vaccine and may not re\ufb02ect\nthe rates observed in clinical"], ["5\nWARNINGS AND PRECAUTIONS", "", "", "", "", "practice."], ["5.1\nManaging Allergic Reactions", "", "", "", "", "The safety experience with Flublok Quadrivalent\nis\nrelevant\nto Flublok because both"], ["Appropriate medical\ntreatment must\nbe\nimmediately", "available", "to manage", "potential", "", "vaccines are manufactured using the same process and have overlapping compositions."], ["anaphylactic reactions following administration of Flublok.", "", "", "", "", "Flublok"], ["5.2\nGuillain-Barr\u00e9 Syndrome", "", "", "", "", ""], ["", "", "", "", "", "Flublok has been administered to and safety data collected from 2497 adults 18 through"], ["If GBS has occurred within 6 weeks of\nreceipt of a prior", "in\ufb02uenza vaccine,", "", "the decision", "", "49 years of age, 972 adults 50 through 64 years of age, and 1078 adults aged 65 years"], ["to give Flublok should be based on careful consideration of the potential bene\ufb01ts and risks.", "", "", "", "", "and older enrolled in \ufb01ve randomized, placebo- or active-controlled clinical\ntrials. Clinical"], ["The\n1976\nswine\nin\ufb02uenza\nvaccine was\nassociated with", "an", "increased", "frequency", "of", "safety data for Flublok are presented from four clinical\ntrials (Studies 1, 2, 3, and 4). Data"], ["Guillain-Barr\u00e9 Syndrome (GBS). Evidence for a causal relation of GBS with other in\ufb02uenza", "", "", "", "", "from a\nplacebo-controlled\ntrial\nin\nadults\n18\nthrough\n49\nyears\nof\nage\n(Study\n1)\nare"], ["vaccines is inconclusive;\nif an excess risk exists,\nit", "is probably slightly more than one", "", "", "", "presented,\nfollowed by data pooled according to age group from Studies 2 and 4 (adults"], ["additional case per 1 million persons vaccinated.", "", "", "", "", "50 through 64 years of age) and Studies 3 and 4 (adults aged 65 years and older)."], ["", "", "", "", "1", ""]]}
{"id": "cc9fb8e9-2138-4a1f-90eb-da5ac3e5cfdb", "page": 2, "type": "table", "data": [["Reactogenicity data from a small Phase 2 trial (Study 5) in adults 18 through 49 years of", "Table 2: Frequency of Solicited Local\nInjection Site Adverse Reactions and"], ["age, 153 of whom received Flublok 135mcg, are not presented. However, subjects from", "Systemic Adverse Reactions within 7 Days of Administration of Flublok or"], ["Study 5 are included in the description of deaths and serious adverse events (SAEs).\nIn", "Comparator\nin Adults 50-64 Years of Age, Studies 2 and 4, Total Vaccinated"], ["all studies local (injection site) and systemic adverse reactions were solicited with the use", "Cohort*,\u2020"], ["of a memory aid for 7 days following vaccination, and unsolicited adverse reactions were", ""], ["", "Flublok\nIIV3\u2020"], ["collected for 28-30 days post-vaccination.\nIn Studies 1- 3 and 5, SAEs were collected for", ""], ["", "N=967\nN=972"], ["6 months post-vaccination via clinic visit or\ntelephone follow up on Day 28,\ntelephone", ""], ["follow up on Day 180, or by spontaneous reporting. Study 4 collected SAEs through 30", "Any\nMod\u2021\nSev\u2021\nAny\nMod\u2021\nSev\u2021"], ["days following receipt of vaccine. Study 4 also actively solicited pre-speci\ufb01ed common", ""], ["", "Local\n%"], ["hypersensitivity-type reactions through 30 days following receipt of vaccine as a primary", ""], ["endpoint.", "Pain\n32\n2\n<1\n37\n<1\n0"], ["Study 1 (NCT00539981)\nincluded 4648 subjects 18 through 49 years of age for safety", ""], ["", "Firmness/Swelling\n7\n2\n<1\n6\n1\n<1"], ["analysis,\nrandomized to receive Flublok (n=2344) or placebo (n=2304)\n(1)\n(see Clinical", ""], ["Studies [14.1]).", "Redness\n6\n2\n<1\n5\n1\n<1"], ["Study 2 (NCT00539864)\nincluded 602 subjects 50 through 64 years of age for safety", ""], ["", "Systemic\n%"], ["analysis,\nrandomized\nto\nreceive\nFlublok\n(n=300)\nor\nanother U.S.-licensed\ntrivalent", ""], ["in\ufb02uenza vaccine (Fluzone, manufactured by Sano\ufb01 Pasteur,\nInc.) as an active control", "Headache\n17\n4\n<1\n16\n3\n<1"], ["(n=302)\n(2).", ""], ["", "Fatigue\n13\n3\n<1\n17\n3\n<1"], ["Study\n3\n(NCT00395174)\nincluded\n869\nsubjects\naged\n65\nyears\nand\nolder\nfor\nsafety", ""], ["analysis,\nrandomized\nto\nreceive\nFlublok\n(n=436)\nor\nanother U.S.-licensed\ntrivalent", "Muscle Pain\n11\n2\n<1\n11\n2\n<1"], ["in\ufb02uenza vaccine (Fluzone) as an active control\n(n=433)\n(3).", ""], ["", "Joint Pain\n8\n2\n<1\n8\n2\n<1"], ["Study 4 (NCT01825200)\nincluded 2627 subjects aged 50 years and older\nfor\nsafety", ""], ["analysis,\nrandomized\nto\nreceive\nFlublok\n(n=1314)\nor\nanother U.S.-licensed\ntrivalent", "Nausea\n6\n1\n0\n5\n<1\n<1"], ["in\ufb02uenza vaccine (A\ufb02uria, manufactured by bioCSL Pty Ltd.) as an active control (n=1313).", ""], ["", "Shivers/Chills\n5\n1\n0\n4\n<1\n<1"], ["Among subjects 50 through 64 years of age, 672 received Flublok and 665 received", ""], ["A\ufb02uria. Among subjects aged 65 years and older, 642 received Flublok and 648 received", "<1\n<1\n<1\n<1\n0\n0\nFever\u00a7"], ["A\ufb02uria.", ""], ["", "NOTE: Data based on the most severe response reported by subjects. Results \u22651%"], ["In a clinical\ntrial of adults 18-49 years of age (Study 1, Table 1)\nthe mean age of", ""], ["", "reported to nearest whole percent;\nresults >0 but <1% reported as <1%."], ["participants was 32.5 years, 59% were female, and 67% were Caucasian (see Clinical", ""], ["Studies [14.1]).", "*Total Vaccinated Cohort is de\ufb01ned as all randomized subjects who received study vaccine"], ["", "according to the treatment actually received and who provided data."], ["Table 1: Frequency of Solicited Local\nInjection Site Adverse Reactions and", "\u2020Pooled Data\nfrom Studies\n2\nand\n4.\nFor Studies\n2\nand\n4,\nthe U.S.-licensed\nIIV3"], ["Systemic Adverse Reactions within 7 Days of Administration of Flublok or", "comparators were Fluzone and A\ufb02uria,\nrespectively. Studies 2 and 4 are registered as"], ["Placebo in Adults 18-49 Years of Age, Study 1, Total Vaccinated Cohort*,\u2020,\u2021", "NCT00539864\nand NCT01825200,\nrespectively,\nunder\nthe National Clinical\nTrials"], ["", "registry."], ["Flublok\nPlacebo", ""], ["", "\u2021Moderate = had it, and it was bad enough to prevent a signi\ufb01cant part of usual activities;"], ["N=2272\nN=2231", ""], ["", "Severe = had it, and it prevented most or all of normal activities, or had to see a doctor"], ["Local\n%\n%", "for prescription medicine."], ["", "\u00a7Fever de\ufb01ned as \u2265100.4\u00b0F (38\u00b0C). Mild (\u2265100.4\u00b0 to <101.1\u00b0F); Moderate (\u2265101.2\u00b0F to"], ["Any\nMod\u00a7\nSev\u00a7\nAny\nMod\u00a7\nSev\u00a7", ""], ["", "<102.2\u00b0F); Severe (\u2265102.2\u00b0F) For fever, 12 Flublok recipients and 5 IIV3 recipients were"], ["", "missing data, making these denominators 964 and 962,\nrespectively."], ["Pain\n37\n2\n<1\n8\n<1\n<1", ""], ["Redness\n4\n<1\n<1\n2\n<1\n<1", ""], ["", "Table 3: Frequency of Solicited Local\nInjection Site Adverse Reactions and"], ["Swelling\n3\n<1\n<1\n2\n<1\n<1", ""], ["", "Systemic Adverse Reactions within 7 Days of Administration of Flublok or"], ["", "Comparator\nin Adults \u226565 Years of Age, Studies 3 and 4, Total Vaccinated"], ["Bruising\n3\n<1\n<1\n3\n<1\n<1", ""], ["", "*,\u2020"], ["", "Cohort"], ["Systemic\n%\n%", ""], ["", "Flublok\nIIV3\u2020"], ["Headache\n15\n3\n<1\n16\n3\n<1", "N=1081\nN=1078"], ["Fatigue\n15\n3\n<1\n14\n3\n<1", "Sev\u2021\nAny\nMod\u2021\nSev\u2021\nAny\nMod\u2021"], ["Muscle Pain\n11\n2\n<1\n7\n<1\n<1", "Local\n%"], ["Nausea\n6\n1\n<1\n5\n1\n<1", "Pain\n19\n<1\n<1\n20\n<1\n<1"], ["Joint pain\n4\n<1\n<1\n4\n<1\n<1", "Redness\n7\n1\n<1\n7\n1\n1"], ["Chills\n3\n<1\n<1\n3\n<1\n<1", "Firmness/Swelling\n7\n2\n<1\n7\n<1\n<1"], ["<1\n<1\n<1\n<1\n<1\n<1\nFever\u00b6", "Systemic\n%"], ["NOTE: Data based on the most severe response reported by subjects. Results \u22651%", "Fatigue\n13\n3\n<1\n15\n2\n<1"], ["reported to nearest whole percent;\nresults >0 but <1% reported as <1%.", ""], ["", "Headache\n10\n<1\n<1\n9\n1\n<1"], ["*Total Vaccinated Cohort is de\ufb01ned as all randomized subjects who received study vaccine", ""], ["according to the treatment actually received and who provided data.", "Muscle Pain\n8\n2\n<1\n8\n1\n<1"], ["\u2020Study 1 is registered as NCT00539981 under\nthe National Clinical Trials registry.", ""], ["", "Joint Pain\n6\n1\n<1\n6\n1\n<1"], ["\u2021Denominators for Study 1: The total number of enrolled,\nrandomized, and vaccinated", ""]]}
{"id": "a21be382-86cb-4ec4-92af-6898f5de1c91", "page": 2, "type": "table", "data": [["reported to nearest whole percent;\nresults >0 but <1% reported as <1%.", ""], ["", "Headache\n10\n<1\n<1\n9\n1\n<1"], ["*Total Vaccinated Cohort is de\ufb01ned as all randomized subjects who received study vaccine", ""], ["according to the treatment actually received and who provided data.", "Muscle Pain\n8\n2\n<1\n8\n1\n<1"], ["\u2020Study 1 is registered as NCT00539981 under\nthe National Clinical Trials registry.", ""], ["", "Joint Pain\n6\n1\n<1\n6\n1\n<1"], ["\u2021Denominators for Study 1: The total number of enrolled,\nrandomized, and vaccinated", ""], ["subjects was 2344 in the Flublok group and 2304 in the placebo group. For all categories", "Shivers/Chills\n5\n<1\n<1\n5\n<1\n<1"], ["except\nfever,\nthe number of subjects with missing values was 72 in the Flublok group", ""], ["and 73 in the Placebo group so that these denominators are 2272 and 2231 respectively.", "Nausea\n4\n<1\n<1\n3\n<1\n<1"], ["For\nfever, 89 Flublok recipients and 104 Placebo recipients were missing data, making", ""], ["", "Fever\u00a7\n3\n<1\n<1\n2\n0\n0"], ["these denominators 2255 and 2200 respectively.", ""], ["\u00a7Moderate = had it, and it was bad enough to prevent a signi\ufb01cant part of usual activities;", "NOTE: Data based on the most severe response reported by subjects. Results \u22651%"], ["Severe = had it, and it prevented most or all of normal activities, or had to see a doctor", "reported to nearest whole percent;\nresults >0 but <1% reported as <1%."], ["for prescription medicine.", "*Total Vaccinated Cohort is de\ufb01ned as all randomized subjects who received study vaccine"], ["\u00b6Fever de\ufb01ned as \u2265100.4\u00b0F (38\u00b0C). Mild (\u2265100.4\u00b0 to <101.1\u00b0F); Moderate (\u2265101.2\u00b0F to", "according to the treatment actually received and who provided data."], ["<102.2\u00b0F); Severe (\u2265102.2\u00b0F)", "\u2020Pooled Data\nfrom Studies\n3\nand\n4.\nFor Studies\n3\nand\n4,\nthe U.S.-licensed\nIIV3"], ["", "comparators were Fluzone and A\ufb02uria,\nrespectively. Studies 3 and 4 are registered as"]]}
{"id": "fe2d05a0-c6fc-420b-9590-0611bd8f1601", "page": 3, "type": "table", "data": [["Among\nadults\n18-49\nyears\nof\nage\n(Studies\n1\nand\n5\npooled),\nthrough\n6 months", "", "Clinical Considerations"], ["post-vaccination,\ntwo deaths were reported, one in a Flublok\nrecipient and one in a", "", "Disease-associated Maternal and/or Embryo/Fetal Risk"], ["placebo recipient. Both deaths occurred more than 28 days following vaccination and", "", "Pregnant women are at\nincreased risk of complications associated with in\ufb02uenza infection"], ["neither was considered vaccine-related. SAEs were reported by 32 Flublok recipients and", "", "compared to non-pregnant women. Pregnant women with in\ufb02uenza may be at\nincreased"], ["35 placebo recipients. One SAE in a Flublok recipient was assessed as possibly related", "", "risk for adverse pregnancy outcomes,\nincluding preterm labor and delivery."], ["", "", "Data"], ["to the vaccine: pleuropericarditis with effusions requiring hospitalization and drainage. No", "", ""], ["", "", "Animal"], ["speci\ufb01c cause was identi\ufb01ed. The patient\nrecovered.", "", ""], ["", "", "In a developmental\ntoxicity study,\nfemale rats were administered Flublok by intramuscular"], ["Among adults 50-64 years of age (Studies 2 and 4 pooled),\nthrough up to 6 months or", "", ""], ["", "", "injection twice prior to mating (35 days and 14 days prior to mating) and on gestation Day"], ["30 days, post- vaccination, respectively,\nthere were no deaths; SAEs were reported by 10", "", ""], ["", "", "6. The total dose was 0.5 mL (divided) on each occasion (a human dose is 0.5 mL). No"], ["subjects, 6 Flublok recipients and 4 IIV3 recipients. One of\nthe SAEs, vasovagal syncope", "", ""], ["", "", "vaccine-related fetal malformations or variations and no adverse effects on pre-weaning"], ["following injection of Flublok, was considered related to administration of study vaccine.", "", "development or\nfemale fertility were observed in the study."], ["Among adults 65 years of age and older (Studies 3 and 4 pooled),\nthrough up to 6 months", "", "8.2\nLactation"], ["or 30 days post-vaccination, respectively,\nthere were 4 deaths, 2 in Flublok recipients and", "", "Risk Summary"], ["2 in IIV3 recipients. None were considered related to the study vaccines. SAEs were", "", "It is not known whether Flublok is excreted in human milk. Data are not available to assess"], ["reported from 80 subjects, 37 Flublok recipients, 43 in IIV3 recipients. No SAEs were", "", "the effects of Flublok on the breastfed infant or on milk production/excretion."], ["considered related to the study vaccines.", "", "The developmental and health bene\ufb01ts of breastfeeding should be considered along with"], ["In Study 1 (adults 18-49 years of age),\nthe most\nfrequent unsolicited adverse events,", "", "the mother\u2019s clinical need for Flublok and any potential adverse effects on the breastfed"], ["", "", "child from Flublok or from the underlying maternal condition. For preventive vaccines,\nthe"], ["occurring\nin\n1%-2% of\nsubjects, were\nnasopharyngitis,\nupper\nrespiratory\ninfection,", "", ""], ["", "", "underlying condition is susceptibility to disease prevented by the vaccine."], ["headache, cough, nasal congestion, pharyngolaryngeal pain, and rhinorrhea.", "", ""], ["", "", "8.4\nPediatric Use"], ["Among adults 50-64 years of age (Studies 2 and 4 pooled),\nthe most\nfrequent unsolicited", "", ""], ["", "", "Data from a randomized, controlled trial demonstrated that children 6 months to less than"], ["adverse events, occurring in 1% of subjects, were diarrhea and cough. Among adults \u226565", "", ""], ["", "", "3\nyears\nof\nage\nhad\ndiminished\nhemagglutinin\ninhibition\n(HI)\nresponses\nto\nFlublok"], ["years of age (Studies 3 and 4 pooled),\nthe most\nfrequent unsolicited adverse events,", "", ""], ["", "", "compared to a U.S.-licensed in\ufb02uenza vaccine approved for use in this population, strongly"], ["occurring in 1% of subjects, were nasopharyngitis and cough.", "", "suggesting that Flublok would not be effective in children younger than 3 years of age (6)."], ["Among adults 50 years of age and older\n(Study 4)\nfor whom the incidence of\nrash,", "", "Safety and effectiveness of Flublok have not been established in children 3 years to less"], ["urticaria, swelling, non- pitting edema, or other potential hypersensitivity reactions were", "", "than 18 years of age."], ["actively solicited for 30 days following vaccination, a total of 2.4% of Flublok recipients and", "", "8.5\nGeriatric Use"], ["1.6% of\nIIV3 recipients reported such events over\nthe 30 day follow-up period. A total of", "", "Data from an efficacy study (Study 6), which included 1759 subjects \u226565 years and 525"], ["1.9% and 0.9% of Flublok and IIV3 recipients,\nrespectively,\nreported these events in the", "", "subjects \u226575\nyears who\nreceived Flublok Quadrivalent,\nare\ninsufficient\nto\ndetermine"], ["7 days following vaccination. Of\nthese solicited events, rash was most\nfrequently reported", "", "whether elderly subjects respond differently from younger subjects (See Clinical Studies"], ["", "", "to Flublok because both vaccines are\n[14]). Data for Flublok Quadrivalent are relevant"], ["(Flublok 1.3%,\nIIV3 0.8%) over\nthe 30 day follow-up period.", "", ""], ["", "", "manufactured using the same process and have overlapping compositions."], ["Flublok Quadrivalent", "", ""], ["", "", "11\nDESCRIPTION"], ["Flublok Quadrivalent has been administered to and safety data collected from 4328 adults", "", ""], ["", "", "Flublok [In\ufb02uenza Vaccine]\nis a sterile, clear, colorless injection containing recombinant"], ["50 years of age and older\n(Study 61) and 998 adults 18-49 years of age (Study 72).", "", ""], ["", "", "hemagglutinin (HA) proteins from three in\ufb02uenza viruses for intramuscular use.\nIt contains"], ["SAEs were collected for 6 months post-vaccination via clinic visit or\nremote contact.", "", ""], ["", "", "is derived\npuri\ufb01ed HA proteins produced in a continuous insect cell\nline (expresSF+\u00ae) that"], ["Study 6 (NCT02285998) enrolled subjects 50 years of age and older,\nrandomized to", "", "from Sf9 cells of\nthe fall armyworm, Spodoptera frugiperda (which is related to moths,"], ["receive\nFlublok Quadrivalent\nor Comparator\n(Fluarix Quadrivalent, manufactured\nby", "", "caterpillars and butter\ufb02ies), and grown in serum-free medium composed of chemically-"], ["[see Clinical Studies (14.1)]. The safety analysis\nGlaxoSmithKline) as an active control", "", "de\ufb01ned\nlipids,\nvitamins,\namino\nacids,\nand mineral\nsalts. Each\nof\nthe\nthree HAs\nis"], ["population included 4328 Flublok Quadrivalent\nrecipients and 4344 Comparator vaccine", "", "expressed in this\ncell\nline using a baculovirus\nvector\n(Autographa californica nuclear"], ["recipients. The mean age of participants was 62.7 years. Overall, 58% of subjects were", "", "polyhedrosis\nvirus), extracted from the cells with Triton X-100 and further puri\ufb01ed by"], ["female,\n80% white/Caucasian,\n18% black/African American,\n0.9% American\nIndian/", "", "column chromatography. The puri\ufb01ed HAs are then blended and \ufb01lled into single-dose"], ["Alaskan Native, 0.4% Asian, 0.2% Native Hawaiian/Paci\ufb01c Islander, 0.7% other\nracial", "", "syringes."], ["groups, and 5% of Hispanic/Latino ethnicity.", "", "Flublok\nis\nstandardized\naccording\nto United States Public Health Service\n(USPHS)"], ["Among adults 50 years of age and older (Study 6), there were no SAEs considered related", "", "requirements. For the 2024-2025 in\ufb02uenza season it\nis formulated to contain 135 mcg HA"], ["to study vaccine.", "", "per 0.5 mL dose, with 45 mcg HA of each of\nthe following 3 in\ufb02uenza virus strains: A/West"], ["Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to", "", "Virginia/30/2022\n(A/Wisconsin/67/2022\npdm09-like\nvirus)\n(H1N1), A/Massachusetts/18/"], ["receive Flublok Quadrivalent or a Comparator\ninactivated in\ufb02uenza vaccine (Fluarix\u00ae", "", "2022 (H3N2) and B/Austria/1359417/2021."], ["Quadrivalent, manufactured by GlaxoSmithKline). The safety analysis population included", "", "A single 0.5 mL dose of Flublok contains sodium chloride (4.4 mg), monobasic sodium"], ["998 recipients of Flublok Quadrivalent and 332 Comparator vaccine recipients. The mean", "", "phosphate (0.2 mg), dibasic sodium phosphate (0.5 mg), and polysorbate 20 (Tween\u00ae20)"], ["age\nof\nparticipants was\n33.5\nyears. Overall,\n65% of\nsubjects were\nfemale,\n59%", "", "(27.5 mcg). Each 0.5 mL dose of Flublok may also contain residual amounts of baculovirus"], ["white/Caucasian, 37% black/African American, 1.0% Native Hawaiian/Paci\ufb01c\nIslander,", "", "and Spodoptera frugiperda cell proteins (\u2264 14.3 mcg), baculovirus and cellular DNA (\u2264 10"], ["0.8% American Indian/Alaskan Native, 0.5% Asian, 1.4% other racial groups, and 16% of", "", "ng), and Triton X-100 (\u2264 100 mcg)."], ["Hispanic/Latino ethnicity.", "", "Flublok contains no egg proteins, antibiotics, or preservatives. The single-dose, pre\ufb01lled"], ["Among adults 18-49 years of age (Study 7), through 6 months post-vaccination, there were", "", "syringes contain no natural\nrubber\nlatex."], ["no SAEs considered related to study vaccine.", "", "12\nCLINICAL PHARMACOLOGY"], ["", "", "12.1 Mechanism of Action"], ["", "", "Flublok contains recombinant HA proteins of\nthe three strains of\nin\ufb02uenza virus speci\ufb01ed"], ["1NCT02285998", "", ""], ["", "", "by health authorities for inclusion in the annual seasonal vaccine. These proteins function"], ["2NCT02290509", "", "as antigens which induce a humoral\nimmune response, measured by hemagglutination"], ["6.2\nPostmarketing Experience", "", "inhibition (HI) antibody)."], ["The following events have been spontaneously\nreported during post approval use of", "", "Antibodies against one in\ufb02uenza virus type or subtype confer\nlimited or no protection"], ["Flublok or Flublok Quadrivalent. They are described because of\nthe temporal relationship,", "", "against another. Furthermore, antibodies to one antigenic variant of\nin\ufb02uenza virus might"], ["the biologic plausibility for a causal\nrelationship to Flublok or Flublok Quadrivalent, and", "", "not\nprotect\nagainst\na\nnew antigenic\nvariant\nof\nthe\nsame\ntype\nor\nsubtype. Frequent"], ["their\npotential\nseriousness.\nBecause\nthese\nevents\nare\nreported\nvoluntarily\nfrom a", "", "development of antigenic variants through antigenic drift\nis the virologic basis for seasonal"], ["population of uncertain size,\nit\nis not always possible to reliably estimate their\nfrequency", "", "epidemics and the reason for the usual replacement of one or more in\ufb02uenza virus strains"], ["or establish a causal\nrelationship to vaccine exposure.", "", "in each year\u2019s in\ufb02uenza vaccine."], ["", "", "13\nNONCLINICAL TOXICOLOGY"], ["Immune system disorders: anaphylaxis, allergic reactions, and other\nforms of hypersen-", "", ""], ["", "", "13.1 Carcinogenesis, Mutagenesis,\nImpairment of Fertility"], ["sitivity (including urticaria).", "", ""], ["", "", "Flublok has not been evaluated for carcinogenic or mutagenic potential, or for impairment"], ["Nervous system disorders:\nfacial palsy (Bell\u2019s palsy), Guillain-Barr\u00e9 syndrome, syncope.", "", ""], ["", "", "of male fertility in animals."], ["8\nUSE IN SPECIFIC POPULATIONS", "", ""], ["", "", "14\nCLINICAL STUDIES"], ["8.1\nPregnancy", "", ""], ["", "", "14.1 Efficacy Against Laboratory-Con\ufb01rmed In\ufb02uenza"], ["Pregnancy Exposure", "", ""], ["", "", "The\nefficacy\nof Flublok\nin\nprotecting\nagainst\nculture-con\ufb01rmed\nin\ufb02uenza\nillness was"], ["There is a pregnancy exposure registry that monitors pregnancy outcomes in women", "", ""], ["", "", "evaluated in a randomized, observer-blind, placebo-controlled multicenter\ntrial conducted"], ["exposed to Flublok.", "", ""], ["", "", "in the U.S. during the 2007-2008 in\ufb02uenza season in adults 18-49 years of age (Study"], ["Healthcare\nproviders\nare\nencouraged\nto\nenroll women who\nreceive\nFlublok\nduring", "", ""], ["", "", "1).\n(1)"], ["pregnancy in Sano\ufb01 Pasteur\nInc.\u2019s vaccination pregnancy registry by calling 1-800-822-", "", ""], ["", "", "Study 1 enrolled and vaccinated 4648 healthy adults (mean age 32.5 years)\nrandomized"], ["2463.", "", ""], ["", "", "in a 1:1 ratio to receive a single dose of Flublok (n=2344) or saline placebo (n=2304)."], ["Risk Summary", "", "Among enrolled subjects, 59% were female, 67% were white, 19% African-American, 2%"], ["All pregnancies have a risk of birth defect,\nloss, or other adverse outcomes.\nIn the U.S.", "", "Asian, < 1% other races, and 11% of Latino/Hispanic ethnicity. Culture-con\ufb01rmed in\ufb02uenza"], ["general population,\nthe estimated background risks of major birth defects and miscarriage", "", "was assessed by active and passive surveillance for\nin\ufb02uenza-like illness (ILI) beginning"], ["in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. Available", "", "2 weeks post-vaccination until\nthe end of\nthe in\ufb02uenza season, approximately 7 months"], ["data on Flublok and Flublok Quadrivalent administered to pregnant women are limited and", "", "post-\nvaccination.\nILI was de\ufb01ned as having at\nleast 2 of 3 symptoms\n(no speci\ufb01ed"], ["insufficient\nto inform vaccine-associated risks in pregnant women.", "", "duration)\nin the following categories: 1)\nfever \u2265 100\u00b0F; 2)\nrespiratory symptoms (cough,"], ["A developmental\nstudy\nof Flublok\nhas\nbeen\nperformed\nin\nrats\nadministered\n0.5 mL", "", "sore throat, or\nrunny nose/stuffy nose); or 3) systemic symptoms (myalgias, arthralgias,"], ["(divided, a single human dose is 0.5 mL) of Flublok prior\nto mating and during gestation.", "", "headache, chills/sweats, or\ntiredness/malaise). For subjects with an episode of\nILI, nasal"], ["This study revealed no evidence of harm to the fetus due to Flublok (see Data).", "", "and throat swab samples were collected for viral culture."], ["", "3", ""]]}
{"id": "6a730463-5481-4046-878f-6ca90e74993d", "page": 4, "type": "table", "data": [["estimate of 44.8% (95% CI 24.4, 60.0). See Table 4 for a presentation of VE by case", "", "", "", ""], ["de\ufb01nition and antigenic similarity.", "", "", "", "All\nrtPCR-positive"], ["", "", "", "", "96\n2.2\n138\n3.2\n0.70\n30 (10, 47)\nIn\ufb02uenza\u2021"], ["", "Table 4: Vaccine Efficacy Against Culture-Con\ufb01rmed In\ufb02uenza in Healthy", "", "", ""], ["", "", "", "", "All\nrtPCR-positive"], ["", "Adults 18-49 Years of Age, Study 1*", "", "", ""], ["", "", "", "", "In\ufb02uenza A\u00a7\n73\n1.7\n114\n2.7\n0.64\n36 (14, 53)"], ["Case de\ufb01nition\nFlublok", "Flublok\nSaline", "", "95%", ""], ["", "", "", "", "All\nrtPCR-positive"], ["(N=2344)", "Vaccine\nPlacebo", "", "Con\ufb01dence", ""], ["", "", "", "", "23\n0.5\n24\n0.6\n0.96\n4 (-72, 46)\nIn\ufb02uenza B\u00a7"], ["", "(N=2304)\nEfficacy\u2020,", "", "Interval", ""], ["", "%", "", "", "All Culture-con\ufb01rmed"], ["Cases,", "Rate,\nCases,\nRate,", "", "", ""], ["", "", "", "", "58\n1.3\n101\n2.3\n0.57\n43 (21, 59)\nProtocol- de\ufb01ned ILI\u00a7,\u00b6"], ["n", "%\nn\n%", "", "", ""], ["", "", "", "", "Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.-"], ["Positive culture with a strain represented in the vaccine", "", "", "", ""], ["", "", "", "", "licensed quadrivalent inactivated in\ufb02uenza vaccine, Fluarix Quadrivalent, manufactured by"], ["CDC-ILI, all\n1", "0.04\n4\n0.2\n75.4", "", "(-148.0,", "GlaxoSmithKline; n=number of\nin\ufb02uenza cases; N=number of subjects in treatment group;"], ["matched strains\u2021,\u00a7", "", "", "99.5)", "RR=relative risk (Attack Rate Flublok/Attack Rate IIV4);\nrVE = [(1-RR) \u00d7 100]."], ["", "", "", "", "*Study 6 is registered as NCT02285998."], ["2\nAny ILI, all", "0.1\n6\n0.3\n67.2", "", "(-83.2,", "\u2020Efficacy Population included all\nrandomized subjects who received study vaccine and"], ["matched strains\u00b6,#", "", "", "96.8)", "provided any follow-up documentation for in\ufb02uenza-like illness beginning at least 14 days"], ["", "", "", "", "post-vaccination. Excluded subjects with protocol deviations that could adversely affect"], ["Positive culture with any strain,", "regardless of match to the vaccine", "", "", ""], ["", "", "", "", "efficacy."], ["CDC-ILI, all\n44", "1.9\n78\n3.4\n44.6", "", "(18.8, 62.6)", "\u2021Primary Analysis. All cases of\nrtPCR-con\ufb01rmed in\ufb02uenza are included. Antigenic char-"], ["strains\u2021,\u00de", "", "", "", "acterization and genetic sequencing to determine similarity of isolates to vaccine antigens"], ["", "", "", "", "were not performed. CDC surveillance data indicated that\nthe majority of\nin\ufb02uenza"], ["Sub-Type A\n26", "1.1\n56\n2.4\n54.4", "", "(26.1, 72.5)", "A/H3N2 wild type viruses were antigenically distinct whereas in\ufb02uenza A/H1N1 and type"], ["", "", "", "", "B viruses were antigenically similar\nto vaccine antigens during the 2014-2015 season."], ["Type B\n18", "0.8\n23\n1.0\n23.1", "", "(-49.0,", ""], ["", "", "", "", "Study 6 met\nthe pre-speci\ufb01ed success criterion for\nthe primary endpoint\n(lower\nlimit of"], ["", "", "", "60.9)", ""], ["", "", "", "", "the 2-sided 95% CI of vaccine efficacy for Flublok Quadrivalent\nrelative to Comparator"], ["64\nAny ILI, all strains\u00b6", "2.7\n114\n4.9\n44.8", "", "(24.4, 60.0)", "should be not\nless than - 20%)."], ["", "", "", "", "in\ufb02uenza A were A/H3N2. Cases of\nin\ufb02uenza B were not\n\u00a7Post hoc analyses. All cases of"], ["Sub-Type A\n41", "1.7\n79\n3.4\n49.0", "", "(24.7, 65.9)", "distinguished by lineage."], ["", "", "", "", "\u00b6Culture of\nrtPCR-positive samples was performed in MDCK cells."], ["Type B\n23", "1.0\n36\n1.6\n37.2", "", "(-8.9, 64.5)", ""], ["*In Study\n1\n(NCT00539981)", "vaccine\nefficacy\nanalyses were", "conducted\non", "the Total", "15\nREFERENCES"]]}
{"id": "07230e69-69ea-49e4-8a26-d7daff4bfe04", "page": 4, "type": "table", "data": [["The\nprimary\nefficacy\nendpoint\nof Study\n1 was Centers\nfor Disease Control-de\ufb01ned", "predominated and that most\nin\ufb02uenza A/H3N2 viruses were antigenically dissimilar while"], ["in\ufb02uenza-like\nillness\n(CDC-ILI) with\na\npositive\nculture\nfor\nan\nin\ufb02uenza\nvirus\nstrain", "A/H1N1 and B viruses were antigenically similar\nto vaccine antigens."], ["antigenically resembling a strain represented in Flublok. CDC-ILI\nis de\ufb01ned as fever of", ""], ["\u2265100\u00b0F\noral\naccompanied\nby\ncough,\nsore\nthroat,\nor\nboth\non\nthe\nsame\nday\nor\non", "Table 5: Relative Vaccine Efficacy (rVE) of Flublok Quadrivalent versus"], ["consecutive days. Attack rates and vaccine efficacy (VE), de\ufb01ned as the reduction in the", "Comparator against Laboratory-Con\ufb01rmed In\ufb02uenza, Regardless of Antigenic"], ["in\ufb02uenza rate for Flublok relative to placebo, were calculated for the total vaccinated cohort", "Similarity to Vaccine Antigens, Adults 50 Years of Age and Older, Study 6"], ["(n=4648).", "(Efficacy Population)*,\u2020"], ["The pre-de\ufb01ned success criterion for\nthe primary efficacy analysis was that\nthe lower", ""], ["", "Flublok"], ["bound of\nthe 95% con\ufb01dence interval (CI) of VE should be at\nleast 40%. Vaccine efficacy", ""], ["", "Quadrivalent\nComparator"], ["against antigenically matched culture-con\ufb01rmed CDC-ILI could not be determined reliably", ""], ["", "(N=4303)\n(N=4301)"], ["because\n96% of\nthe\nin\ufb02uenza\nisolates\nobtained\nfrom subjects\nin Study\n1 were\nnot", "rVE %"], ["antigenically matched to the strains represented in the vaccine. An exploratory analysis", "(95% CI)"], ["", "Attack\nAttack\nRR"], ["of VE of Flublok against all\nstrains,\nregardless of antigenic match,\nisolated from any", "Rate\nRate"], ["subject with an ILI, not necessarily meeting CDC-\nILI criteria, demonstrated an efficacy", "n\n% (n/N)\nn\n% (n/N)"], ["estimate of 44.8% (95% CI 24.4, 60.0). See Table 4 for a presentation of VE by case", ""], ["de\ufb01nition and antigenic similarity.", "All\nrtPCR-positive"], ["", "96\n2.2\n138\n3.2\n0.70\n30 (10, 47)\nIn\ufb02uenza\u2021"], ["Table 4: Vaccine Efficacy Against Culture-Con\ufb01rmed In\ufb02uenza in Healthy", ""], ["", "All\nrtPCR-positive"], ["Adults 18-49 Years of Age, Study 1*", ""], ["", "In\ufb02uenza A\u00a7\n73\n1.7\n114\n2.7\n0.64\n36 (14, 53)"], ["Flublok\nCase de\ufb01nition\nFlublok\nSaline\n95%", ""], ["", "All\nrtPCR-positive"], ["Vaccine\n(N=2344)\nPlacebo\nCon\ufb01dence", ""], ["", "23\n0.5\n24\n0.6\n0.96\n4 (-72, 46)\nIn\ufb02uenza B\u00a7"], ["(N=2304)\nInterval\nEfficacy\u2020,", ""], ["%", "All Culture-con\ufb01rmed"], ["Cases,\nRate,\nCases,\nRate,", ""], ["", "58\n1.3\n101\n2.3\n0.57\n43 (21, 59)\nProtocol- de\ufb01ned ILI\u00a7,\u00b6"], ["n\n%\nn\n%", ""], ["", "Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.-"], ["Positive culture with a strain represented in the vaccine", ""], ["", "licensed quadrivalent inactivated in\ufb02uenza vaccine, Fluarix Quadrivalent, manufactured by"], ["CDC-ILI, all\n1\n0.04\n4\n0.2\n75.4\n(-148.0,", "GlaxoSmithKline; n=number of\nin\ufb02uenza cases; N=number of subjects in treatment group;"], ["matched strains\u2021,\u00a7\n99.5)", "RR=relative risk (Attack Rate Flublok/Attack Rate IIV4);\nrVE = [(1-RR) \u00d7 100]."], ["", "*Study 6 is registered as NCT02285998."], ["2\n0.1\n6\n0.3\n67.2\n(-83.2,\nAny ILI, all", "\u2020Efficacy Population included all\nrandomized subjects who received study vaccine and"], ["96.8)\nmatched strains\u00b6,#", "provided any follow-up documentation for in\ufb02uenza-like illness beginning at least 14 days"], ["", "post-vaccination. Excluded subjects with protocol deviations that could adversely affect"], ["Positive culture with any strain,\nregardless of match to the vaccine", ""], ["", "efficacy."], ["CDC-ILI, all\n44\n1.9\n78\n3.4\n44.6\n(18.8, 62.6)", "\u2021Primary Analysis. All cases of\nrtPCR-con\ufb01rmed in\ufb02uenza are included. Antigenic char-"], ["strains\u2021,\u00de", "acterization and genetic sequencing to determine similarity of isolates to vaccine antigens"], ["", "were not performed. CDC surveillance data indicated that\nthe majority of\nin\ufb02uenza"], ["Sub-Type A\n26\n1.1\n56\n2.4\n54.4\n(26.1, 72.5)", "A/H3N2 wild type viruses were antigenically distinct whereas in\ufb02uenza A/H1N1 and type"], ["", "B viruses were antigenically similar\nto vaccine antigens during the 2014-2015 season."], ["Type B\n18\n0.8\n23\n1.0\n23.1\n(-49.0,", ""], ["", "Study 6 met\nthe pre-speci\ufb01ed success criterion for\nthe primary endpoint\n(lower\nlimit of"], ["60.9)", ""], ["", "the 2-sided 95% CI of vaccine efficacy for Flublok Quadrivalent\nrelative to Comparator"], ["64\n2.7\n114\n4.9\n44.8\n(24.4, 60.0)\nAny ILI, all strains\u00b6", "should be not\nless than - 20%)."], ["", "in\ufb02uenza A were A/H3N2. Cases of\nin\ufb02uenza B were not\n\u00a7Post hoc analyses. All cases of"], ["Sub-Type A\n41\n1.7\n79\n3.4\n49.0\n(24.7, 65.9)", "distinguished by lineage."], ["", "\u00b6Culture of\nrtPCR-positive samples was performed in MDCK cells."], ["Type B\n23\n1.0\n36\n1.6\n37.2\n(-8.9, 64.5)", ""], ["*In Study\n1\n(NCT00539981)\nvaccine\nefficacy\nanalyses were\nconducted\non\nthe Total", "15\nREFERENCES"], ["Vaccinated Cohort (all randomized subjects who received study vaccine according to the", "1. Treanor JJ, El Sahly HM, King J, et. al. Protective efficacy of a trivalent recombinant"], ["treatment actually received and who provided data). Vaccine efficacy (VE) = 1 minus the", "hemagglutinin protein vaccine (FluBlok) against\nin\ufb02uenza in healthy adults: a randomized,"]]}
{"id": "8227a9ec-5839-4090-b579-78504dc223e8", "page": 5, "type": "table", "data": [["\u2022 Flublok contains non-infectious proteins that cannot cause in\ufb02uenza."], ["\u2022 Flublok stimulates the immune system to produce antibodies that help protect against"], ["in\ufb02uenza viruses contained in the vaccine but does not prevent other\nrespiratory"], ["infections."], ["Instruct\nthe vaccine recipient\nto report any adverse events to their healthcare provider"], ["and/or\nto the Vaccine Adverse Event Reporting System (VAERS)."], ["Provide the vaccine recipient with the Vaccine Information Statements which are required"], ["by the National Childhood Vaccine Injury Act of 1986 to be given prior\nto vaccination."], ["These materials are available free of charge at\nthe Centers for Disease Control\n(CDC)"], ["website (www.cdc.gov/vaccines)."], ["Encourage women who receive Flublok while pregnant\nto notify Sano\ufb01 Pasteur\nInc."], ["sano\ufb01pasteurpregnancyregistry.com or by calling 1-800-822-2463 (1-800-VACCINE)."], ["Instruct the vaccine recipient that annual vaccination to prevent in\ufb02uenza is recommended."], ["Manufactured by Protein Sciences Corporation (Meriden, CT) U.S.\nlicense No. 1795."], ["Distributed by Sano\ufb01 Pasteur\nInc."], ["Flublok is a registered trademark of Protein Sciences Corporation."], ["INFB4-FPLR-SL-JUL24\nRx Only"]]}
